Business Overview: MiniMed Group, Inc. (Nasdaq: MMED)

---

Executive Summary

MiniMed Group, Inc. is a global medical technology company developing, manufacturing, and marketing diabetes management products — insulin pumps, continuous glucose monitors (CGMs), consumables, and smart insulin pens — primarily for people with type 1 diabetes and insulin-requiring type 2 diabetes. MiniMed was founded in the early 1980s and acquired by Medtronic in 2001; it is now completing a Separation and Divestment from Medtronic, with Medtronic retaining a controlling equity interest.

With $3.1 billion in FY2026 revenue (up from $2.7 billion) and an installed base of over 640,000 MiniMed 780G customers, MiniMed is one of the largest players in automated insulin delivery, though the business is still posting net losses ($317 million in FY2026) as it absorbs separation costs and invests in next-generation products.

---

1. Core Business Model & How They Work

[ Device R&D (Pumps, CGM, Algorithms) ] ➡️ [ Manufacturing ] ➡️ [ Durable Medical Equipment (DME) Channel / Pharmacy ] ➡️ [ Recurring Consumables, Software & Services Revenue ]

1. Hardware-plus-recurring-consumables model: pumps and CGM transmitters are durable purchases, but infusion sets, reservoirs, sensors, and software subscriptions generate recurring revenue — about 82% of FY2026 revenue came from CGMs, consumables, software, and services rather than one-time device sales.
2. Global distribution: roughly 70% of revenue comes from outside the U.S., with the domestic business sold mainly through the durable medical equipment (DME) channel and a smaller pharmacy channel.
3. Platform integration: MiniMed markets itself as the only company commercializing a fully integrated "Smart Dosing" system — pump, CGM, dosing algorithm, and smart pen — rather than selling components that must be paired with third-party devices.

---

2. Product Portfolio

---

3. Competitive Landscape

            AUTOMATED INSULIN DELIVERY LANDSCAPE
┌──────────────────────────────────────────────────────┐
│ Integrated   │  [MiniMed]                               │
│ Full-Stack   │  (pump + CGM + algorithm + smart pen)    │
│──────────────┼───────────────────────────────────────── │
│ Pump-Focused │  Tandem Diabetes Care (t:slim X2),        │
│              │  Insulet (Omnipod 5, tubeless)             │
│──────────────┼───────────────────────────────────────── │
│ CGM-Focused  │  Dexcom (G6/G7, pairs with rival systems)  │
└──────────────────────────────────────────────────────┘

Named Competitors

• Tandem Diabetes Care — t:slim X2 with Control-IQ, a tubed-pump AID competitor
• Insulet — Omnipod 5, the leading tubeless patch-pump AID system
• Dexcom — G6 and G7 CGMs, which pair with both MiniMed's rivals and third-party systems
• CamDiab (CamAPS FX) and Diabeloop — cited in comparative meta-analyses as additional AID algorithm providers

---

4. Strategic Strengths & Risks

Strengths

• Only fully integrated Smart Dosing platform: MiniMed is the only company commercializing pump, CGM, algorithm, and smart pen as one system, versus rivals who typically focus on one hardware category.
• Large installed base and scale: over 640,000 MiniMed 780G customers and over five million pumps produced since 2001, plus over 2,000 patents and applications.
• Favorable clinical positioning: the company cites real-world and clinical data showing favorable time-in-range results versus competing systems, and top pump-satisfaction ratings in U.S. surveys.
• Pipeline breadth: MiniMed Flex, MiniMed Go, MiniMed Fit, and the Vivera algorithm give the company multiple near-term growth vectors across form factors.

Risks

• Separation overhang: a limited history as a standalone public company, with Medtronic retaining a controlling equity interest and continuing to shape the company's direction.
• Net losses persisting: FY2026 net loss widened to $317 million from $198 million, including a $157 million one-time charge tied to the MiniMed Flex clearance.
• Supplier dependency: Abbott is the exclusive third-party CGM supplier for certain systems and can terminate the relationship in specified circumstances; the filing also flags supply interruption risk, including for Simplera Sync.
• Comparative evidence is indirect: the filing itself acknowledges that no head-to-head trials of modern AID systems exist, so competitive claims rely on meta-analyses and indirect comparisons.
• Adjacent treatment risk: the filing flags GLP-1 drugs and emerging cell therapies as potential long-run threats to device-based diabetes management demand.
• Blackstone funding obligations: royalty and termination terms tied to Blackstone funding agreements add financial complexity during the separation period.

---

5. Financial Overview

---

6. Summary Conclusion

MiniMed Group enters public-company life as the clear scale leader in integrated automated insulin delivery, with a large installed base, a full-stack hardware-plus-software platform that none of its component-focused rivals (Tandem, Insulet, Dexcom) can fully match, and a broad new-product pipeline. The near-term story, however, is about separation execution rather than steady-state economics: net losses are widening even as revenue grows, Medtronic retains control during the transition, and the company's competitive claims rest on indirect rather than head-to-head clinical comparisons. The key question for MiniMed's durability as a standalone company is whether its platform integration converts into profitable growth once separation costs fade.